Please login to the form below

Not currently logged in
Email:
Password:

Europe pharma stocks take fall

European stocks have fallen today in the wake of drug test failures announced by Actelion and AstraZeneca

European stocks have fallen today in the wake of drug test failures announced by both Actelion and AstraZeneca.

Europe's largest biotech Actelion fell 8 per cent after its haemorrhage drug clazosentan failed in a late-stage study, lessening the chances of it making it to market.

AstraZeneca lost 1.5 per cent after the company's experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to its oncology pipeline.

"We've seen a bit of a pause for breath today and it seems like the market is running out of a bit of steam," said Joshua Raymond, markets strategist at City Index.

27th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics